To evaluate clinical and functional findings in 23 patients undergoing a successful first trial of NIV in a pneumological ward for AECOPD.
We studied 23 patients undergoing a successful first trial of NIV in a pneumological ward for AECOPD without any other comorbidity [pH: 7.34±0.03, PaCO2 65.2±11.4 mmHg PaO2: 50.3 ±11.2 mmHg respiratory rate (RR): 26±4 bpm, dyspnea (by Borg scale BS): 5.9±1.9, Glasgow Coma Scale (GCS): 14.9±0.2, heart rate (HR): 97.1±11.7 bpm and systolic arterial blood pressure (ABP) 140.3±10.0 mmHg]. NIV was considered as successful and stopped when pH was normalized without tachypnoea or signs of respiratory muscle fatigue for more than 1 day and NIV time were the hours elapsed from starting of NIV to the last hour of actual ventilation. For each patient length of COPD (LD: 17.0±13.0 years), number of AECOPD as defined by worsening in symptoms requiring change in medical therapy in the last two years preceding NIV (2.3±1.5) were recorded.
NIV time was 72.7±10.7 hours and showed a significant high correlation with number of AECOPD in the 2 years preceding NIV (R2: 0.69, p= 0.0001) No correlation was found between NIV time and blood gases, BS GCS, RR, HR, and ABP before starting of NIV nor with LD respectively.
We conclude that high number of annual AECOPD may influence the time of NIV required to recover from ARF due to AECOPD.
All pharmacological, and non pahrmacological tools should be used to reduce frequency of exacerbations.DISCLOSURE: N. Ambrosino, None.